Hana Biosciences News
Most Popular Hana Biosciences Story
ALSO NOTED: Neuren buys Hamilton Pharma; Merck pulls out of MethyGene collaboration; Par licenses Zensana rights; and much more
> New Zealand's Neuren is acquiring Washington D.C.-based Hamilton Pharmaceuticals for $4.4 million in a deal that delivers the license for a drug called Motiva, a late-stage preclinical compound... Read more...
Latest Headlines
- April 30, 2008
- October 31, 2007
- August 29, 2007
- August 29, 2006
- May 21, 2006
- March 29, 2006
- March 16, 2006
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
